1. A compounds of Formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts thereof,
wherein
A is substituted or unsubstituted 5-10 membered bicyclic or polycyclic fully or partially
unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from O, N, or S;
D is selected from CR1 or N;
G is selected from –C(O)OR1, –C(O)NRaRb, -SOpR1, -NR1SO2R1 or 5-7 membered
monocyclic fully or partially unsaturated heterocyclic ring having 1-4 heteroatoms
independently selected from O, N or S;
R1 is selected from hydrogen, C1-6 haloalkyl, C1-6 alkyl, C6-10 aryl, C5-10 heteroaryl, C3-6
cycloalkyl or C5-10 heterocyclyl, wherein C6-10 aryl, C3-6 cycloalkyl, C5-10 heteroaryl, and C5-10
heterocyclyl are optionally substituted with C1-6 alkyl;
R2, R3, and R4 are independently selected from hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C2-6
alkenyl, C2-6 alkynyl, C1-6 alkoxy, C(O)R1, R1C(O)NRaRb, -OC(O)R1, R6, -(CRaRb)mC(O)R6, -
(CRaRb)mNR7R8, -NRaC(O)-, -C1-6 alkoxy C(O)NRaRb, -SO2NRaRb-, -NRaC(O)NRaRb, C1-6
alkoxyamino, azido, cyano, halogen, hydroxy, C1-6 alkylhydroxy, C1-6 haloalkyl, perhalo C1-6
alkyl, -C(S)Ra, –C(O)OR1, C1-6 alkyl C(O)ORb, OC(O) C1-6 alkyloxy, ORaC(O)ORb- C1-6
alkylOC(O) O C1-6 alkyloxy, -SO3H, -S(O)pR6, -S(O)2NR7R8 C1-6 alkylthio or nitro;
R6 is selected from the group consisting of hydrogen, -(CRaRb)mOR6, halogen, C1-6 haloalkyl,
-(CRaRb)mC(O)R6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6

cycloalkyl, or C5-10 heterocyclyl, wherein C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, C5-10
heterocyclyl are optionally substituted with C1-6 alkyl,
wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and
C5-10 heterocyclyl are optionally substituted with one or more substituents selected from
hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, halogen, C1-6 haloalkyl, perhalo-C1-6 alkyl,
cyano, -cyano C1-6 alkyl-, amino, –C(O)OR1, OR5, -OC(O)R6, -(CRaRb)mC(O)NR7R8, -
NR6C(O)R6, -SR6, -S(O)pR6, -S(O)2NR7R8 or -NR6S(O)2R6;
R5, R7, and R8 are independently selected from the group consisting of hydrogen, -
(CRaRb)mOR6, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10
aryl, C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl, wherein , C6-10 aryl, C5-10 heteroaryl,
C3-6 cycloalkyl, and C5-10 heterocyclyl are optionally substituted with C1-6 alkyl, or
R7, and R8 can be taken together to form a monocyclic or a bicyclic saturated or partially
unsaturated carbocyclyl or heterocyclyl ring optionally having 1-5 heteroatoms selected from
O, N, or S, wherein the monocyclic or a bicyclic saturated or partially unsaturated
carbocyclyl or heterocyclyl ring is further optionally substituted with 1 to 4 substituents
independently selected from halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, nitro, cyano, -
(CRaRb)mOR6, -SR6, -(CRaRb)mNR7R8, oxo, C1-6 alkylsulfonyl, -(CRaRb)mCOOR6, -
(CRaRb)mC(O)NR7R8, C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, or C5-10
heteroaryl,wherein C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, and C5-10 heteroaryl are
optionally substituted with C1-6 alkyl;
Ra, and Rb are independently selected from the group consisting of hydrogen, -OR6, halogen,
C1-6 haloalkyl, perhalo C1-6 alkyl, -SOpR1, and C1-6 alkyl; or
Ra, and Rb can be taken together to form a monocyclic or a bicyclic saturated or partially
unsaturated carbocyclyl or heterocyclyl ring optionally having 1-5 heteroatoms selected from
O, N, or S;
m is 0 to 4;
n is 0 to 3;
p is 0-2.
2. The compounds of Formula (I) their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts thereof, as claimed in claim 1, wherein A is substituted or unsubstituted 5-10 membered bicyclic or polycyclic fully or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from O, N, or S; D is selected from CR1, or N;

G is selected from –C(O)OR1, –C(O)NRaRb, -NR1SO2R1 or 5 membered monocyclic fully or partially unsaturated heterocyclic ring having 1-4 heteroatoms independently selected from O, N, or S;
R1 is selected from hydrogen, C1-6 haloalkyl, C1-6 alkyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, or C5-10 heterocyclyl, wherein C6-10 aryl, C3-6 cycloalkyl, C5-10 heteroaryl, and C5-10 heterocyclyl are optionally substituted with C1-6 alkyl;
R2, R3, and R4 are independently selected from hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C(O)R1, R1C(O)NRaRb, -OC(O)R1, R6, -(CRaRb)mC(O)R6, -(CRaRb)mNR7R8, -NRaC(O)-, -C1-6 alkoxy C(O)NRaRb, -SO2NRaRb-, -NRaC(O)NRaRb, NRaOH, C1-6 alkoxyamino, azido, cyano, halogen, hydroxy, C1-6 alkylhydroxy, C1-6 haloalkyl, perhalo C1-6 alkyl, -C(S)Ra, C(O)OR1, C1-6 alkyl C(O)ORb, OC(O) C1-6 alkyloxy, ORaC(O)ORb- C1-6 alkylOC(O) O C1-6 alkyloxy, -SO3H, -S(O)pR6, -S(O)2NR7R8 C1-6 alkylthio or nitro;
R6 is selected from the group consisting of hydrogen, -(CRaRb)mOR6, halogen, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, or C5-10 heterocyclyl, wherein C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl are optionally substituted with C1-6 alkyl,
wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and C5-10 heterocyclyl are optionally substituted with one or more substituents selected from hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, halogen, C1-6 haloalkyl, perhalo-C1-6 alkyl, cyano, -cyano C1-6 alkyl-, amino, –C(O)OR1, OR5, -OC(O)R6, -(CRaRb)mC(O)NR7R8, -NR6C(O)R6, -SR6, -S(O)pR6, -S(O)2NR7R8, or -NR6S(O)2R6;
R5, R7, and R8 are independently selected from the group consisting of hydrogen, -(CRaRb)mOR6, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl, wherein , C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and C5-10 heterocyclyl are optionally substituted with C1-6 alkyl or R5, R7 and R8 can be taken together to form a monocyclic or a bicyclic saturated or partially unsaturated carbocyclyl or heterocyclyl ring optionally having 1-5 heteroatoms selected from O, N, S, wherein the monocyclic or a bicyclic ring carbocyclyl or heterocyclyl is further optionally substituted with 1 to 4 substituents independently selected from halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, nitro, cyano, -(CRaRb)mOR6, -SR6, -(CRaRb)mNR7R8, oxo, C1-6 alkylsulfonyl, -(CRaRb)mCOOR6, -(CRaRb)mC(O)NR7R8, C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, or C5-10 heteroaryl, wherein C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl;

Ra, and Rb are independently selected from the group consisting of hydrogen, -OR6, halogen,
C1-6 haloalkyl, perhalo C1-6 alkyl, -SOpR1, and C1-6 alkyl; or
Ra, and Rb can be taken together to form a monocyclic or a bicyclic ring saturated or partially
unsaturated optionally having 1-5 heteroatoms selected from O, N or S;
m is 0 to 4;
n is 1 to 3;
p is 0-2.
3. The compounds of Formula (I) their tautomers, polymorphs, stereoisomers, prodrugs,
solvates, pharmaceutically acceptable salts thereof, as claimed in claim 1, wherein
A is substituted or unsubstituted 5-10 membered bicyclic or polycyclic fully or partially
unsaturated heterocyclic ring having 1-5 heteroatom independently selected from O, N, or S;
D is selected from CR1, or N;
G is selected from –C(O)OR1, –C(O)NRaRb, -NR1SO2R1, or 5 membered monocyclic fully or
partially unsaturated heterocyclic ring having 1-4 heteroatoms independently selected from
O, N or S;
R1 is selected from hydrogen, C1-6 haloalkyl, C1-6 alkyl, C5-10 heteroaryl, or C3-6 cycloalkyl,
wherein C3-6 cycloalkyl, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl;
R2, R3, and R4 are independently selected from hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C2-6
alkenyl, C2-6 alkynyl, C1-6 alkoxy, C(O)R1, R1C(O)NRaRb, -OC(O)R1, R6, -(CRaRb)mC(O)R6, -
(CRaRb)mNR7R8, -NRaC(O)-, -C1-6 alkoxy C(O)NRaRb, -SO2NRaRb-, -NRaC(O)NRaRb,
NRaOH, C1-6 alkoxyamino, azido, cyano, halogen, hydroxy, C1-6 alkyl hydroxy, C1-6
haloalkyl, perhalo C1-6 alkyl, -C(S)Ra, C(O)OR1, C1-6 alkyl C(O)ORb, OC(O) C1-6 alkyloxy,
ORaC(O)ORb- C1-6 alkylOC(O) O C1-6 alkyloxy, -SO3H, -S(O)pR6, -S(O)2NR7R8 C1-6 alkylthio
or nitro;
R6 is selected from the group consisting of hydrogen, -(CRaRb)mOR6, halogen, C1-6 haloalkyl,
-(CRaRb)mC(O)R6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6
cycloalkyl, or C5-10 heterocyclyl, wherein C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, C5-10
heterocyclyl are optionally substituted with C1-6 alkyl;
wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and
C5-10 heterocyclyl are optionally substituted with one or more substituents selected from
hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, halogen, C1-6 haloalkyl, perhalo-C1-6 alkyl,
cyano, -cyano C1-6 alkyl-, amino, –C(O)OR1, OR5, -OC(O)R6, -(CRaRb)mC(O)NR7R8, -
NR6C(O)R6, -SR6, -S(O)pR6, -S(O)2NR7R8, or -NR6S(O)2R6;

R5, R7, and R8 are independently selected from the group consisting of hydrogen, -(CRaRb)mOR6, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl, wherein , C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and C5-10 heterocyclyl are optionally substituted with C1-6 alkyl or R7 and R8 can be taken together to form a monocyclic or a bicyclic saturated or partially unsaturated carbocyclyl or heterocyclyl ring optionally having 1-5 heteroatoms selected from O, N or S, wherein the monocyclic or a bicyclic ring carbocyclyl or heterocyclyl is further optionally substituted with 1 to 4 substituents independently selected from halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, nitro, cyano, -(CRaRb)mOR6, -SR6, -(CRaRb)mNR7R8, oxo, C1-6 alkylsulfonyl, -(CRaRb)mCOOR6, -(CRaRb)mC(O)NR7R8, C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, or C5-10 heteroaryl,wherein C3-6 cycloalkyl, C6-10 aryl, C5-10, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl;
Ra, and Rb are independently selected from the group consisting of hydrogen, -OR6, halogen, C1-6 haloalkyl, perhalo C1-6 alkyl, -SOpR1, and C1-6 alkyl or
Ra, and Rb can be taken together to form a monocyclic or a bicyclic ring saturated or partially unsaturated optionally having 1-5 heteroatoms selected from O, N or S; m is 0 to 4; n is 1 to 3; p is 0-2.
4. The compounds of Formula (I) their tautomers, polymorphs, stereoisomers, prodrugs,
solvates, pharmaceutically acceptable salts thereof, as claimed in claim 1, wherein
A is substituted or unsubstituted 5-10 membered bicyclic or polycyclic unsaturated or
partially unsaturated heterocyclic ring having 1-5 heteroatom independently selected from O,
N or S;
D is selected from CR1 or N;
G is selected from –C(O)OR1, –C(O)NRaRb, -NR1SO2R1 or 5 membered monocyclic fully or
partially unsaturated heterocyclic ring having 1-4 heteroatoms independently selected from
O, N, or S;
R1 is selected from hydrogen, C1-6 haloalkyl, C1-6 alkyl, C5-10 heteroaryl, or C3-6 cycloalkyl,
wherein C3-6 cycloalkyl, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl;
R2, R3, and R4 are independently selected from hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C1-6
alkoxy, C(O)R1, R1C(O)NRaRb, -OC(O)R1, R6, -(CRaRb)mC(O)R6, -(CRaRb)mNR7R8, -
NRaC(O)-, -C1-6 alkoxy C(O)NRaRb, -NRaC(O)NRaRb, NRaOH, C1-6 alkoxyamino, azido,

cyano, halogen, hydroxy, C1-6 alkyl hydroxy, C1-6 haloalkyl, perhalo C1-6 alkyl, C(O)OR1, C1-6 alkyl C(O)ORb, OC(O) C1-6 alkyloxy, ORaC(O)ORb- C1-6 alkylOC(O) O C1-6 alkyloxy, or nitro;
R6 is selected from the group consisting of hydrogen, -(CRaRb)mOR6, halogen, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, or C5-10 heterocyclyl, wherein C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl are optionally substituted with C1-6 alkyl;
wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and heterocyclyl are optionally substituted with one or more substituents selected from hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, halogen, C1-6 haloalkyl, perhalo-C1-6 alkyl, cyano, -cyano C1-6 alkyl-, amino, –C(O)OR1, OR5, -OC(O)R6, -(CRaRb)mC(O)NR7R8, -NR6C(O)R6, -SR6, -S(O)pR6, -S(O)2NR7R8, or -NR6S(O)2R6;
R5, R7, and R8 are independently selected from the group consisting of hydrogen, -(CRaRb)mOR6, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl, wherein , C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and C5-10 heterocyclyl are optionally substituted with C1-6 alkyl or R7 and R8 can be taken together to form a monocyclic or a bicyclic saturated or partially unsaturated carbocyclyl or heterocyclyl ring optionally having 1-5 heteroatoms selected from O, N or S, wherein the monocyclic or a bicyclic ring carbocyclyl or heterocyclyl is further optionally substituted with 1 to 4 substituents independently selected from halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, nitro, cyano, -(CRaRb)mOR6, -SR6, -(CRaRb)mNR7R8, oxo, C1-6 alkylsulfonyl, -(CRaRb)mCOOR6, -(CRaRb)mC(O)NR7R8, C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, or C5-10 heteroaryl,wherein C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl;
Ra, and Rb are independently selected from the group consisting of hydrogen, -OR6, halogen, C1-6 haloalkyl, perhalo C1-6 alkyl, -SOpR1, and C1-6 alkyl or
Ra, and Rb can be taken together to form a monocyclic or a bicyclic ring saturated or partially unsaturated optionally having 1-5 heteroatoms selected from O, N or S; m is 0 to 4; n is 1 to 3; p is 0-2.
5. The compounds of Formula (I) their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts thereof, as claimed in claim 1, wherein

A is substituted or unsubstituted 5-10 membered bicyclic or polycyclic unsaturated or partially unsaturated heterocyclic ring having 1-5 heteroatom independently selected from O, N or S;
D is selected from CR1 or N;
G is selected from –C(O)OR1, –C(O)NRaRb, -NR1SO2R1 or 5 membered monocyclic fully unsaturated or partially unsaturated heterocyclic ring having 1-4 heteroatom independently selected from O, N, or S;
R1 is selected from hydrogen, C1-6 haloalkyl, C1-6 alkyl, C5-10 heteroaryl, or C3-6 cycloalkyl, wherein C3-6 cycloalkyl, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl; R2, R3, and R4 are independently selected from hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkoxy, C(O)R1, R1C(O)NH2, -OC(O)R1, C(O)OR1, R6, -(CRaRb)mC(O)R6, -(CRaRb)mNR7R8, -NRaC(O)-, -C1-6 alkoxy C(O)NRaRb, -NRaC(O)NRaRb, NRaOH, C1-6 alkoxyamino, azido, cyano, halogen, hydroxy, C1-6 alkyl hydroxy, C1-6 haloalkyl, perhalo C1-6 alkyl, C1-6 alkyl C(O)ORb, OC(O) C1-6 alkyloxy, ORaC(O)ORb- C1-6 alkylOC(O) O C1-6 alkyloxy, or nitro; R6 is selected from the group consisting of hydrogen, -(CRaRb)mOR6, halogen, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C5-10 heteroaryl, C3-6 cycloalkyl, or C5-10 heterocyclyl, wherein C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl are optionally substituted with C1-6 alkyl; wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and C5-10 heterocyclyl are optionally substituted with one or more substituents selected from hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, halogen, C1-6 haloalkyl, perhalo-C1-6 alkyl, cyano, -cyano C1-6 alkyl-, amino, –C(O)OR1, OR5, -OC(O)R6, -(CRaRb)mC(O)NR7R8, -NR6C(O)R6, -SR6, -S(O)pR6, -S(O)2NR7R8 or -NR6S(O)2R6;
R5, R7, and R8 are independently selected from the group consisting of hydrogen, -(CRaRb)mOR6, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl, wherein , C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and C5-10 heterocyclyl are optionally substituted with C1-6 alkyl or R7 and R8 can be taken together to form a monocyclic or a bicyclic saturated or partially unsaturated carbocyclyl or heterocyclyl ring optionally having 1-5 heteroatoms selected from O, N, or S, wherein the monocyclic or a bicyclic ring carbocyclyl or heterocyclyl is further optionally substituted with 1 to 4 substituents independently selected from halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, nitro, cyano, -(CRaRb)mOR6, -SR6, -(CRaRb)mNR7R8, oxo, C1-6 alkylsulfonyl, -(CRaRb)mCOOR6, -(CRaRb)mC(O)NR7R8, C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, or C5-10 heteroaryl,wherein C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl;

Ra, and Rb are independently selected from the group consisting of hydrogen, -OR6, halogen,
C1-6 haloalkyl, perhalo C1-6 alkyl, -SOpR1, and C1-6 alkyl or
Ra, and Rb can be taken together to form a monocyclic or a bicyclic ring saturated or partially
unsaturated optionally having 1-5 heteroatoms selected from O, N, or S;
m is 0 to 4;
n is 1 to 3;
p is 0-2.
6. The compounds of Formula (I) their tautomers, polymorphs, stereoisomers, prodrugs,
solvates, pharmaceutically acceptable salts thereof, as claimed in claim 1, wherein
A is substituted or unsubstituted 5-10 membered bicyclic or polycyclic unsaturated or
partially unsaturated heterocyclic ring having 1-5 heteroatom independently selected from O,
N or S;
D is selected from CR1 or N;
G is selected from –C(O)OR1, –C(O)NRaRb, -NR1SO2R1 or 5 membered monocyclic fully
unsaturated or partially unsaturated heterocyclic ring having 1-4 heteroatom independently
selected from O, N, or S;
R1 is selected from hydrogen, C1-6 haloalkyl, C1-6 alkyl, C5-10 heteroaryl, or C3-6 cycloalkyl,
wherein C3-6 cycloalkyl, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl;
R2, R3, and R4 are independently selected from hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C1-6
alkoxy, C(O)R1, R1C(O)NH2, -OC(O)R1, R6, C(O)OR1, -(CRaRb)mC(O)R6, -(CRaRb)mNR7R8,
-NRaC(O)-, -C1-6 alkoxy C(O)NRaRb, -NRaC(O)NRaRb, NRaOH, C1-6 alkoxyamino, azido,
cyano, halogen, hydroxy, C1-6 alkyl hydroxy, C1-6 haloalkyl, perhalo C1-6 alkyl, C1-6 alkyl
C(O)ORb, OC(O) C1-6 alkyloxy, ORaC(O)ORb- C1-6 alkylOC(O) O C1-6 alkyloxy, or nitro;
R6 is selected from the group consisting of hydrogen, -(CRaRb)mOR6, halogen, C1-6 haloalkyl,
-(CRaRb)mC(O)R6, C1-6 alkyl, C5-10 heteroaryl, C3-6 cycloalkyl, or C5-10 heterocyclyl, wherein
C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl are optionally substituted with C1-6 alkyl;
wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and
C5-10 heterocyclyl are optionally substituted with one or more substituents selected from
hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, halogen, C1-6 haloalkyl, perhalo-C1-6 alkyl,
cyano, -cyano C1-6 alkyl-, amino, –C(O)OR1, OR5, -OC(O)R6, -(CRaRb)mC(O)NR7R8, -
NR6C(O)R6, -SR6, -S(O)pR6, -S(O)2NR7R8, or -NR6S(O)2R6;
R5, R7, and R8 are independently selected from the group consisting of hydrogen, -
(CRaRb)mOR6, C1-4 haloalkyl, -(CRaRb)mC(O)R6, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C6-8

aryl, 5-7 membered heteroaryl, C3-5 cycloalkyl, 5-7 membered heterocyclyl, wherein , C6-8 aryl, 5-7 membered heteroaryl, C3-5 cycloalkyl, and 5-7 membered heterocyclyl are optionally substituted with C1-6 alkyl or
R7 and R8 can be taken together to form a monocyclic or a bicyclic saturated or partially unsaturated carbocyclyl or heterocyclyl ring optionally having 1-5 heteroatoms selected from O, N, or S, wherein the monocyclic or a bicyclic ring carbocyclyl or heterocyclyl is further optionally substituted with 1 to 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, nitro, cyano, -(CRaRb)mOR6, -SR6, -(CRaRb)mNR7R8, oxo, C1-6 alkylsulfonyl, -(CRaRb)mCOOR6, -(CRaRb)mC(O)NR7R8, C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, or C5-10 heteroaryl,wherein C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl;
Ra, and Rb are independently selected from the group consisting of hydrogen, -OR6, halogen, C1-6 haloalkyl, perhalo C1-6 alkyl, -SOpR1, and C1-6 alkyl or
Ra, and Rb can be taken together to form a monocyclic or a bicyclic ring saturated or partially unsaturated optionally having 1-5 heteroatoms selected from O, N or S; m is 0 to 4; n is 1 to 3; p is 0-2.
7. The compounds of Formula (I) their tautomers, polymorphs, stereoisomers, prodrugs,
solvates, pharmaceutically acceptable salts thereof, as claimed in claim 1, wherein
A is substituted or unsubstituted C5-10 bicyclic or polycyclic unsaturated or partially
unsaturated heterocyclic ring having 1-5 heteroatom independently selected from O, N or S;
D is selected from CR1 or N;
G is selected from –C(O)OR1, –C(O)NRaRb, -NR1SO2R1 or 5 membered monocyclic fully
unsaturated or partially unsaturated heterocyclic ring having 1-4 heteroatom independently
selected from O, N, or S;
R1 is selected from hydrogen, C1-6 haloalkyl, C1-6 alkyl, C5-10 heteroaryl, or C3-6 cycloalkyl,
wherein C3-6 cycloalkyl, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl;
R2, R3, and R4 are independently selected from hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C1-6
alkoxy, C(O)R1, R1C(O)NH2, -OC(O)R1, R6, C(O)OR1, -(CRaRb)mC(O)R6, -(CRaRb)mNR7R8,
-NRaC(O)-, -C1-6 alkoxy C(O)NRaRb, -NRaC(O)NRaRb, NRaOH, C1-6 alkoxyamino, azido,
cyano, halogen, hydroxy, C1-6 alkyl hydroxy, C1-6 haloalkyl, perhalo C1-6 alkyl, C1-6 alkyl
C(O)ORb, OC(O) C1-6 alkyloxy, ORaC(O)ORb- C1-6 alkylOC(O) O C1-6 alkyloxy, or nitro;

R6 is selected from the group consisting of hydrogen, -(CRaRb)mOR6, halogen, C1-6 haloalkyl,
-(CRaRb)mC(O)R6, C1-6 alkyl, C5-10 heteroaryl, C3-6 cycloalkyl, or C5-10 heterocyclyl, wherein
C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl are optionally substituted with C1-6 alkyl;
wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and
C5-10 heterocyclyl are optionally substituted with one or more substituents selected from
hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, halogen, C1-6 haloalkyl, perhalo-C1-6 alkyl,
cyano, -cyano C1-6 alkyl-, amino, –C(O)OR1, OR5, -OC(O)R6, -(CRaRb)mC(O)NR7R8, -
NR6C(O)R6, -SR6, -S(O)pR6, -S(O)2NR7R8 or -NR6S(O)2R6;
R5, R7, and R8 are independently selected from the group consisting of hydrogen, -
(CRaRb)mOR6, C1-4 haloalkyl, -(CRaRb)mC(O)R6, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C6-8
aryl, 5-7 membered heteroaryl, C3-5 cycloalkyl, 5-7 membered heterocyclyl, wherein , C6-8
aryl, 5-7 membered heteroaryl, C3-5 cycloalkyl, and 5-7 membered heterocyclyl are optionally
substituted with C1-6 alkyl; or
R7 and R8 can be taken together to form a monocyclic or a bicyclic saturated or partially
unsaturated carbocyclyl or heterocyclyl ring optionally having 1-4 heteroatoms selected from
O, N, or S, wherein the monocyclic or a bicyclic ring carbocyclyl or heterocyclyl is further
optionally substituted with 1 to 4 substituents independently selected from halo, C1-6 alkyl,
cyano, -(CRaRb)mOR6, -SR6, oxo, -(CRaRb)mCOOR6, C3-6 cycloalkyl, C6-10 aryl, C5-10
heterocyclyl, or C5-10 heteroaryl, wherein C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, and
C5-10 heteroaryl are optionally substituted with C1-6 alkyl;
Ra, and Rb are independently selected from the group consisting of hydrogen, -OR6, halogen,
C1-6 haloalkyl, perhalo C1-6 alkyl, -SOpR1, and C1-6 alkyl; or
Ra, and Rb can be taken together to form a monocyclic or a bicyclic ring saturated or partially
unsaturated optionally having 1-5 heteroatoms selected from O, N, or S;
m is 0 to 4;
n is 1 to 3;
p is 0-2.
8. The compounds of Formula (I) their tautomers, polymorphs, stereoisomers, prodrugs,
solvates, pharmaceutically acceptable salts thereof, as claimed in claim 1, wherein
A is substituted or unsubstituted 5-10 membered bicyclic or polycyclic unsaturated or
partially unsaturated heterocyclic ring having 1-5 heteroatom independently selected from O,
N, or S;
D is selected from CR1 or N;

G is selected from –C(O)OR1, –C(O)NRaRb, -NR1SO2R1 or 5 membered monocyclic fully
unsaturated or partially unsaturated heterocyclic ring having 1-4 heteroatom independently
selected from O, N, or S;
R1 is selected from hydrogen, C1-6 haloalkyl, C1-6 alkyl, C5-10 heteroaryl, or C3-6 cycloalkyl,
wherein C3-6 cycloalkyl, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl;
R2, R3, and R4 are independently selected from hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C1-6
alkoxy, C(O)R1, R1C(O)NH2, -OC(O)R1, R6, C(O)OR1, -(CRaRb)mC(O)R6, -(CRaRb)mNR7R8,
-NRaC(O)-, -C1-6 alkoxy C(O)NRaRb, -NRaC(O)NRaRb, NRaOH, C1-6 alkoxyamino, azido,
cyano, halogen, hydroxy, C1-6 alkyl hydroxy, C1-6 haloalkyl, perhalo C1-6 alkyl, C1-6 alkyl
C(O)ORb, OC(O) C1-6 alkyloxy, ORaC(O)ORb- C1-6 alkylOC(O) O C1-6 alkyloxy, or nitro;
R6 is selected from the group consisting of hydrogen, -(CRaRb)mOR6, halogen, C1-6 haloalkyl,
-(CRaRb)mC(O)R6, C1-6 alkyl, C5-10 heteroaryl, C3-6 cycloalkyl, or C5-10 heterocyclyl, wherein
C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl are optionally substituted with C1-6 alkyl;
wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and
C5-10 heterocyclyl are optionally substituted with one or more substituents selected from
hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, halogen, C1-6 haloalkyl, perhalo-C1-6 alkyl,
cyano, -cyano C1-6 alkyl-, amino, –C(O)OR1, OR5, -OC(O)R6, -(CRaRb)mC(O)NR7R8, -
NR6C(O)R6, -SR6, -S(O)pR6, -S(O)2NR7R8, or -NR6S(O)2R6;
R5, R7, and R8 are independently selected from the group consisting of hydrogen, -
(CRaRb)mOR6, C1-4 haloalkyl, -(CRaRb)mC(O)R6, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C6-8
aryl, 5-7 membered heteroaryl, C3-5 cycloalkyl, 5-7 membered heterocyclyl, wherein , C6-8
aryl, 5-7 membered heteroaryl, C3-5 cycloalkyl, and 5-7 membered heterocyclyl are optionally
substituted with C1-6 alkyl; or
R7 and R8 can be taken together to form a monocyclic or a bicyclic saturated or partially
unsaturated carbocyclyl or heterocyclyl ring optionally having 1-4 heteroatoms selected from
O, N, or S, wherein the monocyclic or a bicyclic ring carbocyclyl or heterocyclyl is further
optionally substituted with 1 to 4 substituents independently selected from halo, C1-6 alkyl,
cyano, -(CRaRb)mOR6, -SR6, oxo, -(CRaRb)mCOOR6, C3-6 cycloalkyl, C6-10 aryl, C5-10
heterocyclyl, or C5-10 heteroaryl, wherein C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, and
C5-10 heteroaryl are optionally substituted with C1-6 alkyl;
Ra, and Rb are independently selected from the group consisting of hydrogen, -OR6, halogen,
C1-6 haloalkyl, perhalo C1-6 alkyl, -SOpR1, and C1-6 alkyl; or
m is 0 to 3;
n is 1 to 3;

9. The compound of Formula (I) as claimed in any one of the claims 1-8, tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts thereof, which is selected from a group consisting of:
2-[3-[4-(8-isoquinolyloxy)-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A1), 2-[3-[4-phthalazin-5-yloxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A2), 3-[3-[4-phthalazin-5-yloxy-2-(trifluoromethyl)phenoxy]phenyl]propanoic acid (A3), 2-[3-[4-(8-chlorophthalazin-5-yl)oxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A4), 2-[3-[4-(1-methylindazol-7-yl)oxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A5), 2-[3-[4-(6-quinolyloxy)-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A6),
3-[3-[4-imidazo[1,2-a]pyridin-8-yloxy-2-(trifluoromethyl)phenoxy]phenyl]propanoic acid
(A7),
2-[3-[4-[(5-fluoro-8-isoquinolyl)oxy]-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A8), 2-[3-[4-quinazolin-5-yloxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A9),
3-[3-[4-[(2-methyl-3,4-dihydro-1H-isoquinolin-8-yl)oxy]-2-(trifluoromethyl) phenoxy]
phenyl]propanoic acid (A10),
3-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yloxy)-2-(trifluoromethyl)phenoxy]phenyl]propanoic acid (A11),
3-[3-[4-(8-quinolyloxy)-2-(trifluoromethyl)phenoxy]phenyl]propanoic acid (A12), 3-[3-[4-(4-quinolyloxy)-2-(trifluoromethyl)phenoxy]phenyl]propanoic acid (A13), 3-[3-[4-(5-isoquinolyloxy)-2-(trifluoromethyl)phenoxy]phenyl]propanoic acid (A14), 2-[3-[4-(2-methylindazol-4-yl)oxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A15), 2-[3-[4-(1-methylindazol-4-yl)oxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A16), 2-[3-[4-([1,2,4]triazolo[4,3-a]pyridin-5-yloxy)-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A17),
2-[3-[4-(3,4-dihydro-2H-1,4-benzoxazin-6-yloxy)-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A18),
2-[3-[4-([1,2,4]triazolo[4,3-a]pyridin-7-yloxy)-2-(trifluoromethyl)phenoxy] phenyl]acetic
acid (A19),
2-[3-[4-[1-(oxetan-3-yl)indol-6-yl]oxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A20),
2-[3-[4-[1-(oxetan-3-yl)indazol-6-yl]oxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid
(A21),

2-[3-[4-[2-(oxetan-3-yl)indazol-6-yl]oxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid
(A22),
2-[3-[4-[1-(oxetan-3-yl)indazol-5-yl]oxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid
(A23),
2-[3-[4-[2-(oxetan-3-yl)indazol-5-yl]oxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid
(A24),
2-[3-[4-[3-(oxetan-3-yl)benzotriazol-5-yl]oxy-2-(trifluoromethyl) phenoxy]phenyl]acetic acid (A25),
2-[3-[4-[3-(oxetan-3-yl)benzimidazol-5-yl]oxy-2-(trifluoromethyl)phenoxy] phenyl]acetic acid (A26),
2-[3-[4-[2-methyl-3-(oxetan-3-yl)benzimidazol-5-yl]oxy-2-(trifluoromethyl) phenoxy] phenyl]acetic acid (A27),
2-[3-[2-(difluoromethyl)-4-[2-methyl-3-(oxetan-3-yl)benzimidazol-5-yl]oxy-phenoxy] phenyl]acetic acid (A28),
2-[3-[4-[1-(oxetan-3-yl)imidazo[4,5-b]pyridin-6-yl]oxy-2-(trifluoromethyl) phenoxy] phenyl]acetic acid (A29),
2-[3-[4-[1-(oxetan-3-yl)pyrrolo[2,3-b]pyridin-6-yl]oxy-2-(trifluoromethyl) phenoxy] phenyl]acetic acid (A30),
6-[4-[3-(carboxymethyl)phenoxy]-3-(trifluoromethyl)phenoxy]imidazo[1,5-a]pyridine-3-carboxylic acid (A31),
2-[3-[4-[1-(carboxymethyl)indol-5-yl]oxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid
(A32),
2-[3-[4-[1-(carboxymethyl)indol-6-yl]oxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid
(A33),
3-[4-[4-(8-isoquinolyloxy)-2-(trifluoromethyl)phenoxy]phenyl]propanoic acid (A34),
3-[3-[4-(2-methylindazol-5-yl)oxy-2-(trifluoromethyl)phenoxy]phenyl]propanoic acid (A35),
2-[3-[[5-(8-isoquinolyloxy)-3-(trifluoromethyl)-2-pyridyl]oxy]phenyl]acetic acid (A36),
3-[3-[4-imidazo[1,2-a]pyridin-5-yloxy-2-(trifluoromethyl)phenoxy]phenyl]propanoic acid
(A37),
2-[3-[2-cyclopropyl-4-(8-isoquinolyloxy)phenoxy]phenyl]acetic acid (A38), 2-[3-[2-cyclopropyl-4-[2-methyl-3-(oxetan-3-yl)benzimidazol-5-yl]oxy-phenoxy] phenyl]acetic acid (A39),
2-[3-[4-[(1-chloro-8-isoquinolyl)oxy]-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A40), 2-[3-[4-[(1-methyl-8-isoquinolyl)oxy]-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A41),

3-[3-[4-(8-isoquinolyloxy)-2-(trifluoromethyl)phenoxy]phenyl]propanoic acid (A42),
3-[3-[4-(1,2,3,4-tetrahydroisoquinolin-8-yloxy)-2-(trifluoromethyl) phenoxy] phenyl]
propanoic acid (A43),
3-[3-[4-indan-1-yloxy-2-(trifluoromethyl)phenoxy]phenyl]propanoic acid (A44),
3-[3-[4-(1H-indazol-5-yloxy)-2-(trifluoromethyl)phenoxy]phenyl]propanoic acid (A45),
2-[3-[4-[(3-cyano-1H-indazol-5-yl)oxy]-2-(trifluoromethyl) phenoxy]phenyl]acetic acid
(A46),
5-[4-[3-(carboxymethyl)phenoxy]-3-(trifluoromethyl)phenoxy]-1H-indazole-3-carboxylic
acid (A47),
2-[3-[4-(1H-indazol-4-yloxy)-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A48),
2-[3-[4-imidazo[1,5-a]pyridin-5-yloxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (B1),
2-[3-[4-imidazo[1,5-a]pyridin-8-yloxy-2-(trifluoromethyl) phenoxy]phenyl]acetic acid (B2),
2-[3-[4-(3-methylimidazo[1,5-a]pyridin-5-yl)oxy-2-(trifluoromethyl)phenoxy]phenyl]acetic
acid (B3),
2-[3-[4-(3-methylimidazo[1,5-a]pyridin-8-yl)oxy-2-(trifluoromethyl)phenoxy]phenyl]acetic
acid (B4),
2-[3-[4-[3-(oxetan-3-yl)imidazo[1,5-a]pyridin-6-yl]oxy-2-(trifluoromethyl) phenoxy] phenyl]
acetic acid (B5),
2-[3-[4-(8-isoquinolyloxy)-2-(trifluoromethyl)phenoxy]phenyl]-N-methylsulfonyl-acetamide
(C1),
3-[3-[4-(8-isoquinolyloxy)-2-(trifluoromethyl)phenoxy]phenyl]propanamide (C2),
2-[3-[4-(8-isoquinolyloxy)-2-(trifluoromethyl)phenoxy]phenyl]acetamide (C3),
8-[4-[3-[2-(4H-1,2,4-triazol-3-yl)ethyl]phenoxy]-3-(trifluoromethyl)phenoxy]isoquinoline
(D1),
8-[4-[3-[2-(1H-tetrazol-5-yl)ethyl]phenoxy]-3-(trifluoromethyl)phenoxy]isoquinoline (D2),
8-[4-[3-(1H-tetrazol-5-ylmethyl)phenoxy]-3-(trifluoromethyl) phenoxy]isoquinoline (D3),
and
2-[3-[4-(8-isoquinolyloxy)-3-(trifluoromethyl)phenoxy]phenyl]acetic acid (E1).
10. A process of preparation of compounds of Formula (I) as claimed in any of claims 1 to 9 or its tautomers, polymorphs, stereoisomers, prodrugs, solvate, co-crystals or pharmaceutically acceptable salts thereof.
11. The process as claimed in claimed in claim 10, wherein the compounds of Formula I are obtained by reacting compounds of Formula II, and compounds of Formula III.

12. The process as claimed in claimed in claim 11, wherein the G of Formula II is selected from –C(O)OR1, –C(O)NRaRb, -NR1SO2R1 or 5-7 membered monocyclic fully or partially unsaturated heterocyclic ring having 1-4 heteroatom independently selected from O, N, or S; R1 is selected from hydrogen, C1-6 haloalkyl, C1-6 alkyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, or C5-10 heterocyclyl, wherein C6-10 aryl, C3-6 cycloalkyl, C5-10 heteroaryl, and C5-10 heterocyclyl are optionally substituted with C1-6 alkyl; R2, and R3 are independently selected from hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C(O)R1, R1C(O)NH2, -OC(O)R1, R6, C(O)OR1, -(CRaRb)mC(O)R6, -(CRaRb)mNR7R8, -NRaC(O)-, -C1-6 alkoxy C(O)NRaRb, -SO2NRaRb-, -NRaC(O)NRaRb, NRaOH, C1-6 alkoxyamino, azido, cyano, halogen, hydroxy, C1-6 alkyl hydroxy, C1-6 haloalkyl, perhalo C1-6 alkyl, -C(S)Ra, C1-6 alkyl C(O)ORb, OC(O) C1-6 alkyloxy, ORaC(O)ORb- C1-6 alkylOC(O) O C1-6 alkyloxy, -SO3H, -S(O)pR6, -S(O)2NR7R8 C1-6 alkylthio, or nitro;
R6 is selected from the group consisting of hydrogen, -(CRaRb)mOR6, halogen, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, or C5-10 heterocyclyl, wherein C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl are optionally substituted with C1-6 alkyl;
wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and C5-10 heterocyclyl are optionally substituted with one or more substituents selected from hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, halogen, C1-6 haloalkyl, perhalo-C1-6 alkyl, cyano, -cyano C1-6 alkyl-, amino, –C(O)OR1, OR5, -OC(O)R6, -(CRaRb)mC(O)NR7R8, -NR6C(O)R6, -SR6, -S(O)pR6, -S(O)2NR7R8, or -NR6S(O)2R6;
R5, R7, and R8 are independently selected from the group consisting of hydrogen, -(CRaRb)mOR6, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl, wherein , C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and C5-10 heterocyclyl are optionally substituted with C1-6 alkyl; or

R7 and R8 can be taken together to form a monocyclic or a bicyclic saturated or partially unsaturated carbocyclyl or heterocyclyl ring optionally having 1-5 heteroatoms selected from O, N, or S, wherein the monocyclic or a bicyclic ring carbocyclyl or heterocyclyl is further optionally substituted with 1 to 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, nitro, cyano, -(CRaRb)mOR6, -SR6, -(CRaRb)mNR7R8, oxo, C1-6 alkylsulfonyl, -(CRaRb)mCOOR6, -(CRaRb)mC(O)NR7R8, C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, or C5-10 heteroaryl,wherein C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl; Ra, and Rb are independently selected from the group consisting of hydrogen, -OR6, halogen, C1-6 haloalkyl, perhalo C1-6 alkyl, -SOpR1, and C1-6 alkyl; or Ra, and Rb can be taken together to form a monocyclic or a bicyclic ring saturated or partially unsaturated optionally having 1-5 heteroatoms selected from O, N, or S; m is 0 to 4; n is 0 to 3; p is 0-2; and A of Formula III is substituted or unsubstituted 5-10 membered bicyclic or polycyclic fully or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from O, N or S; R4 of Formula III is independently selected from hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C(O)R1, R1C(O)NH2, -OC(O)R1, R6, -(CRaRb)mC(O)R6, -(CRaRb)mNR7R8, -NRaC(O)-, -C1-6 alkoxy C(O)NRaRb, -SO2NRaRb-, -NRaC(O)NRaRb, NRaOH, C1-6 alkoxyamino, azido, cyano, halogen, hydroxy, C1-6 alkyl hydroxy, C1-6 haloalkyl, perhalo C1-6 alkyl, -C(S)Ra, , C1-6 alkyl C(O)ORb, OC(O) C1-6 alkyloxy, ORaC(O)ORb- C1-6 alkylOC(O) O C1-6 alkyloxy, -SO3H, -S(O)pR6, -S(O)2NR7R8 C1-6 alkylthio, or nitro;
R6 is selected from the group consisting of hydrogen, -(CRaRb)mOR6, halogen, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, or C5-10 heterocyclyl, wherein C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl are optionally substituted with C1-6 alkyl,
wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and C5-10 heterocyclyl are optionally substituted with one or more substituents selected from hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, halogen, C1-6 haloalkyl, perhalo-C1-6 alkyl, cyano, -cyano C1-6 alkyl-, amino, –C(O)OR1, OR5, -OC(O)R6, -(CRaRb)mC(O)NR7R8, -NR6C(O)R6, -SR6, -S(O)pR6, -S(O)2NR7R8, or -NR6S(O)2R6;
R5, R7, and R8 are independently selected from the group consisting of hydrogen, -(CRaRb)mOR6, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl, wherein , C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and C5-10 heterocyclyl are optionally substituted with C1-6 alkyl;or

R7, and R8 can be taken together to form a monocyclic or a bicyclic saturated or partially unsaturated carbocyclyl or heterocyclyl ring optionally having 1-5 heteroatoms selected from O, N, or S, wherein the monocyclic or a bicyclic ring carbocyclyl or heterocyclyl is further optionally substituted with 1 to 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, nitro, cyano, -(CRaRb)mOR6, -SR6, -(CRaRb)mNR7R8, oxo, C1-6 alkylsulfonyl, -(CRaRb)mCOOR6, -(CRaRb)mC(O)NR7R8, C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, or C5-10 heteroaryl,wherein C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl;
Ra, and Rb are independently selected from the group consisting of hydrogen, -OR6, halogen, C1-6 haloalkyl, perhalo C1-6 alkyl, -SOpR1, and C1-6 alkyl; or
Ra, and Rb can be taken together to form a monocyclic or a bicyclic ring saturated or partially unsaturated optionally having 1-5 heteroatoms selected from O, N or S; and m is 0 to 4; and X and Y is independently selected from halogen, CF₃ SO₃ -, boronate ester or boronic acid, provided X and Y cannot be the same.
13. A pharmaceutical composition comprising a compound of Formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, or a pharmaceutically acceptable salt thereof as claimed in any of claims 1 to 9 together with a pharmaceutically acceptable carrier, optionally in combination with one or more other pharmaceutical compositions.
14. The pharmaceutical composition as claimed in claim 13, wherein the composition is in the form of a tablet, capsule, powder, syrup, solution, aerosol, or suspension.
15. The compound as claimed in any of the claims 1 – 9, for use in the manufacture of a medicament of disease states mediated by GPR91.
16. A method for the treatment and/or prevention of various diseases, including cancer and infectious diseases, comprising administering to a subject suffering from the proliferative disorder or cancer, a therapeutically effective amount of the compound as claimed in any one of claims 1 – 9, or the pharmaceutical composition as claimed in claim 13, or 14, with other clinically relevant cytotoxic agents or non-cytotoxic agents to a subject in need thereof.
17. Use of the compounds as claimed in any one of claims 1 – 9, or the pharmaceutical composition as claimed in claim 13 or 14, for the treatment and/or prevention of various diseases including proliferative disorder or cancer; or treatment of cancer together with other clinically relevant cytotoxic agents or non-cytotoxic agents.
18. A method for the treatment of neovascularization, macular degeneration, diabetic
nephropathy, liver diseases, inflammation, cancer, metabolic diseases, cardiovascular disease,
hypertension, non alcoholic steatohepetitis (NAASH), fatty liver disease (FLD), non

alcoholic fatty liver disease (NAFLD), retinal angiogenesis , said method comprising administering a combination of the compounds as claimed in any of claims 1 – 9, or the pharmaceutical composition as claimed in claim 13 or 14, with other clinically relevant cytotoxic agents or non-cytotoxic agents to a subject in need thereof.
19. A method of treatment of as claimed in claim 18, said method comprising administering a combination of the compounds as claimed in any of claims 1 – 9, or the pharmaceutical composition as claimed in claim 13 or 14, with other clinically relevant immune modulators agents to a subject in need of thereof.